GPR18 is a G protein-coupled receptor that plays a critical role in inflammation resolution and tissue homeostasis. The receptor is activated by multiple endogenous ligands including resolvin D2 (RvD2), N-arachidonyl glycine (NAGly), and endocannabinoids 12. Upon RvD2 binding, GPR18 couples to Gαs proteins and activates cAMP-PKA signaling pathways, promoting specialized pro-resolving mediator (SPM) functions that facilitate inflammation resolution and tissue repair 3. The receptor demonstrates significant therapeutic potential across multiple disease contexts. In cardiovascular diseases, the RvD2-GPR18 axis provides protective effects against atherosclerosis and other cardiovascular pathologies by promoting anti-inflammatory responses 4. In gastrointestinal disorders, GPR18 activation by RvD2 prevents TRPV1 sensitization and reduces visceral hypersensitivity, showing promise for IBS treatment 1. The receptor also mediates endocannabinoid signaling, with anandamide enhancing macrophage efferocytosis through both CB2 and GPR18 pathways 2. GPR18 modulates immune cell function, particularly macrophage phagocytosis and pro-resolving responses, making it an attractive therapeutic target for inflammatory diseases 5. The growing body of evidence positions GPR18 as a promising biomarker and therapeutic target for cardiovascular, metabolic, and inflammatory disorders 3.